[425] Semler Scientific, Inc. Business Combination Communication
Strive, Inc. posted a Rule 425 communication regarding its proposed business combination with Semler Scientific, Inc. The notice states Strive intends to file a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement of Strive, a proxy statement of Semler Scientific, and a prospectus of Strive.
A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler stockholders to seek their approval. The communication emphasizes forward‑looking statement cautions and clarifies it is not an offer to sell or solicit the purchase of securities. Documents will be available on the SEC’s website and the companies’ investor sites.
Strive, Inc. ha pubblicato una comunicazione secondo la Regola 425 riguardante la proposta di fusione aziendale con Semler Scientific, Inc. L'avviso indica che Strive intende presentare una Form S-4 per registrare le azioni ordinarie di Classe A da emettere nella transazione, che comprenderà una dichiarazione informativa di Strive, una dichiarazione proxy di Semler Scientific e un prospetto di Strive.
Una informativa definitiva/Proxy Statement/Prospectus sarà inviata agli azionisti di Semler per ottenere la loro approvazione. La comunicazione enfatizza le avvertenze sulle dichiarazioni forward‑looking e chiarisce che non si tratta di un'offerta di vendita o di sollecitare l'acquisto di titoli. I documenti saranno disponibili sul sito della SEC e sui siti degli investitori delle due società.
Strive, Inc. publicó una comunicación de la Regla 425 con respecto a su propuesta de combinación comercial con Semler Scientific, Inc. El aviso señala que Strive tiene la intención de presentar un Form S-4 para registrar las acciones comunes de Clase A que serán emitidas en la transacción, que incluirá una declaración informativa de Strive, una declaración de poder de Semler Scientific y un prospecto de Strive.
Una declaración informativa definitiva/Declaración de poder/ Prospecto será enviada a los accionistas de Semler para buscar su aprobación. La comunicación enfatiza cautelas sobre declaraciones prospectivas y aclara que no es una oferta para vender ni solicitar la compra de valores. Los documentos estarán disponibles en el sitio web de la SEC y en los sitios de inversores de las empresas.
Strive, Inc.는 Semler Scientific, Inc.와의 제안된 사업 결합에 관한 Rule 425 커뮤니케이션을 게시했습니다. 공지에 따르면 Strive은 거래에서 발행될 Class A 보통주를 등록하기 위해 Form S-4를 제출할 의도가 있으며, 여기에는 Strive의 안내자료, Semler Scientific의 위임장자료 및 Strive의 투자설명서가 포함될 예정입니다.
Semler 주주들에게 승인을 얻기 위해 확정된 정보성 안내서/위임장/투자설명서가 발송될 예정입니다. 이 커뮤니케이션은 전향적 진술에 대한 주의사항을 강조하고 이것이 증권의 매매를 제안하거나 청약하는 것이 아님을 명확히 합니다. 문서는 SEC 웹사이트와 양사의 투자자 사이트에서 확인할 수 있습니다.
Strive, Inc. a publié une communication selon la règle 425 concernant son projet de fusion avec Semler Scientific, Inc. L'avis indique que Strive a l'intention de déposer un Form S-4 pour enregistrer des actions ordinaires de classe A à émettre dans la transaction, qui incluront une déclaration d'information de Strive, une déclaration de procuration de Semler Scientific et un prospectus de Strive.
Une Information Statement/Proxy Statement/Prospectus définitive sera envoyée aux actionnaires de Semler pour obtenir leur approbation. La communication met l'accent sur les avertissements concernant les déclarations prospectives et précise qu'il ne s'agit pas d'une offre de vendre ou de solliciter l'achat de valeurs mobilières. Les documents seront disponibles sur le site de la SEC et sur les sites des investisseurs des entreprises.
Strive, Inc. veröffentlichte eine Mitteilung gemäß Regel 425 im Zusammenhang mit dem vorgeschlagenen Unternehmenszusammenschluss mit Semler Scientific, Inc. Die Mitteilung besagt, dass Strive beabsichtigt, ein Form S-4 einzureichen, um Stammaktien der Klasse A zu registrieren, die in der Transaktion ausgegeben werden sollen, was eine Informationsmitteilung von Strive, eine Proxy-Erklärung von Semler Scientific und einen Prospekt von Strive umfassen wird.
Eine definitive Information Statement/Proxy Statement/Prospectus wird an die Semler-Aktionäre versandt, um deren Zustimmung zu suchen. Die Mitteilung betont Hinweise zu zukunftsgerichteten Aussagen und klärt, dass sie kein Angebot zum Verkauf oder zur Aufforderung zum Kauf von Wertpapieren ist. Dokumente werden auf der Website der SEC und den Investoren-Seiten der Unternehmen verfügbar sein.
Strive, Inc. نشرت اتصالًا وفق القاعدة 425 بخصوص اندماجها المقترح مع Semler Scientific, Inc. ويذكر الإشعار أن Strive تعتزم تقديم Form S-4 لتسجيل أسهم Class A عادية ستصدر في الصفقة، والتي ستشمل بيان معلومات من Strive، وبيان تفويض من Semler Scientific، ونشرة اكتتاب من Strive.
سيتم إرسال بيان معلومات نهائي/بيان تفويض/نشرة اكتتاب إلى مساهمي Semler للسعي للحصول على موافقتهم. يؤكد الاتصال على تحذيرات البيانات المستقبلية ويوضح أنه ليس عرضاً لبيع أو طلب شراء الأوراق المالية. ستكون المستندات متاحة على موقع هيئة الأوراق المالية والبورصة الالكتروني ومواقع المستثمرين للشركتين.
- None.
- None.
Insights
Advance notice of a proposed Strive–Semler merger; next milestone is Strive’s Form S-4 and Semler stockholder vote materials.
This communication confirms a proposed business combination between Strive, Inc. and Semler Scientific, Inc. It signals process progression: Strive intends to file a Form S-4 to register Strive Class A shares to be issued in the transaction, and the combined information statement/proxy/prospectus will be sent to Semler stockholders for approval.
The document is procedural and includes extensive forward-looking disclaimers. It does not disclose deal terms, consideration, valuation, or closing timelines. It highlights typical uncertainties around timing, integration, and performance, and notes that results may differ from expectations. The filing also identifies that directors and officers of both companies may be “participants in the solicitation,” a standard proxy-solicitation disclosure.
Key items to watch: the S-4 filing and when it becomes effective, the mailing of the Information Statement/Proxy Statement/Prospectus, and the date of the Semler stockholder vote. Reference materials include Strive’s Form 8-Ks filed on
Strive, Inc. ha pubblicato una comunicazione secondo la Regola 425 riguardante la proposta di fusione aziendale con Semler Scientific, Inc. L'avviso indica che Strive intende presentare una Form S-4 per registrare le azioni ordinarie di Classe A da emettere nella transazione, che comprenderà una dichiarazione informativa di Strive, una dichiarazione proxy di Semler Scientific e un prospetto di Strive.
Una informativa definitiva/Proxy Statement/Prospectus sarà inviata agli azionisti di Semler per ottenere la loro approvazione. La comunicazione enfatizza le avvertenze sulle dichiarazioni forward‑looking e chiarisce che non si tratta di un'offerta di vendita o di sollecitare l'acquisto di titoli. I documenti saranno disponibili sul sito della SEC e sui siti degli investitori delle due società.
Strive, Inc. publicó una comunicación de la Regla 425 con respecto a su propuesta de combinación comercial con Semler Scientific, Inc. El aviso señala que Strive tiene la intención de presentar un Form S-4 para registrar las acciones comunes de Clase A que serán emitidas en la transacción, que incluirá una declaración informativa de Strive, una declaración de poder de Semler Scientific y un prospecto de Strive.
Una declaración informativa definitiva/Declaración de poder/ Prospecto será enviada a los accionistas de Semler para buscar su aprobación. La comunicación enfatiza cautelas sobre declaraciones prospectivas y aclara que no es una oferta para vender ni solicitar la compra de valores. Los documentos estarán disponibles en el sitio web de la SEC y en los sitios de inversores de las empresas.
Strive, Inc.는 Semler Scientific, Inc.와의 제안된 사업 결합에 관한 Rule 425 커뮤니케이션을 게시했습니다. 공지에 따르면 Strive은 거래에서 발행될 Class A 보통주를 등록하기 위해 Form S-4를 제출할 의도가 있으며, 여기에는 Strive의 안내자료, Semler Scientific의 위임장자료 및 Strive의 투자설명서가 포함될 예정입니다.
Semler 주주들에게 승인을 얻기 위해 확정된 정보성 안내서/위임장/투자설명서가 발송될 예정입니다. 이 커뮤니케이션은 전향적 진술에 대한 주의사항을 강조하고 이것이 증권의 매매를 제안하거나 청약하는 것이 아님을 명확히 합니다. 문서는 SEC 웹사이트와 양사의 투자자 사이트에서 확인할 수 있습니다.
Strive, Inc. a publié une communication selon la règle 425 concernant son projet de fusion avec Semler Scientific, Inc. L'avis indique que Strive a l'intention de déposer un Form S-4 pour enregistrer des actions ordinaires de classe A à émettre dans la transaction, qui incluront une déclaration d'information de Strive, une déclaration de procuration de Semler Scientific et un prospectus de Strive.
Une Information Statement/Proxy Statement/Prospectus définitive sera envoyée aux actionnaires de Semler pour obtenir leur approbation. La communication met l'accent sur les avertissements concernant les déclarations prospectives et précise qu'il ne s'agit pas d'une offre de vendre ou de solliciter l'achat de valeurs mobilières. Les documents seront disponibles sur le site de la SEC et sur les sites des investisseurs des entreprises.
Strive, Inc. veröffentlichte eine Mitteilung gemäß Regel 425 im Zusammenhang mit dem vorgeschlagenen Unternehmenszusammenschluss mit Semler Scientific, Inc. Die Mitteilung besagt, dass Strive beabsichtigt, ein Form S-4 einzureichen, um Stammaktien der Klasse A zu registrieren, die in der Transaktion ausgegeben werden sollen, was eine Informationsmitteilung von Strive, eine Proxy-Erklärung von Semler Scientific und einen Prospekt von Strive umfassen wird.
Eine definitive Information Statement/Proxy Statement/Prospectus wird an die Semler-Aktionäre versandt, um deren Zustimmung zu suchen. Die Mitteilung betont Hinweise zu zukunftsgerichteten Aussagen und klärt, dass sie kein Angebot zum Verkauf oder zur Aufforderung zum Kauf von Wertpapieren ist. Dokumente werden auf der Website der SEC und den Investoren-Seiten der Unternehmen verfügbar sein.
Strive, Inc. نشرت اتصالًا وفق القاعدة 425 بخصوص اندماجها المقترح مع Semler Scientific, Inc. ويذكر الإشعار أن Strive تعتزم تقديم Form S-4 لتسجيل أسهم Class A عادية ستصدر في الصفقة، والتي ستشمل بيان معلومات من Strive، وبيان تفويض من Semler Scientific، ونشرة اكتتاب من Strive.
سيتم إرسال بيان معلومات نهائي/بيان تفويض/نشرة اكتتاب إلى مساهمي Semler للسعي للحصول على موافقتهم. يؤكد الاتصال على تحذيرات البيانات المستقبلية ويوضح أنه ليس عرضاً لبيع أو طلب شراء الأوراق المالية. ستكون المستندات متاحة على موقع هيئة الأوراق المالية والبورصة الالكتروني ومواقع المستثمرين للشركتين.
Strive, Inc. 发布了关于其拟议与 Semler Scientific, Inc. 的业务合并的 Rule 425 通讯。通知指出 Strive 打算提交 Form S-4 以注册在交易中发行的 A 类普通股，其中将包括 Strive 的信息声明、Semler Scientific 的代理声明以及 Strive 的招股说明书。
将向 Semler 的股东发送最终信息声明/代理声明/招股说明书以寻求其批准。该通讯强调对前瞻性声明的警告，并澄清这不是出售或招揽购买证券的要约。文件将可在美国证券交易委员会的网站及两家公司投资者网站上找到。
Filed by Strive, Inc.
(Commission File No.: 001-41612)
Pursuant to Rule 425 of the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Semler Scientific, Inc.
(Commission File No.: 001-36305)
The following communication was posted on X.com by Ben Pham, Chief Financial Officer of Strive, Inc. (“Strive”), on October 28, 2025, in connection with Strive’s proposed business combination with Semler Scientific, Inc. (“Semler Scientific”).
Cautionary Statement Regarding Forward-Looking Statements
Certain statements herein and the documents incorporated herein by reference may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Rule 175 promulgated thereunder, and Section 21E of the Exchange Act and Rule 3b-6 promulgated thereunder, which statements involve inherent risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements regarding the outlook and expectations of Strive and Semler Scientific, respectively, with respect to the proposed transaction, the strategic benefits and financial benefits of the proposed transaction, including the expected impact of the proposed transaction on the combined company's future financial performance, the timing of the closing of the proposed transaction, and the ability to successfully integrate the combined businesses. Such statements are often characterized by the use of qualified words (and their derivatives) such as "may," "will," "anticipate," "could," "should," "would," "believe," "contemplate," "expect," "estimate," "continue," "plan," "project," "predict," "potential," "assume," "forecast," "target," "budget," "outlook," "trend," "guidance," "objective," "goal," "strategy," "opportunity," and "intend," as well as words of similar meaning or other statements concerning opinions or judgment of Strive, Semler Scientific or their respective management about future events. Forward-looking statements are based on assumptions as of the time they are made and are subject to risks, uncertainties and other factors that are difficult to predict with regard to timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results expressed or implied by such forward-looking statements. Such risks, uncertainties and assumptions, include, among others, the following:
| · | the occurrence of any event, change or other circumstances that could give rise to the right of one or both of Strive and Semler Scientific to terminate the merger agreement between Strive and Semler Scientific; |
| · | the possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not received or satisfied on a timely basis or at all; |
| · | the outcome of any legal proceedings that may be instituted against Strive or Semler Scientific or the combined company; |
| · | the possibility that the anticipated benefits of the proposed transaction, including anticipated cost savings and strategic gains, are not realized when expected or at all, including as a result of changes in, or problems arising from, implementation of Bitcoin treasury strategies and risks associated with Bitcoin and other digital assets, general economic and market conditions, interest and exchange rates, monetary policy, and laws and regulations and their enforcement; |
| · | the possibility that the integration of the two companies may be more difficult, time-consuming or costly than expected; |
| · | the possibility that the proposed transaction may be more expensive or take longer to complete than anticipated, including as a result of unexpected factors or events; |
| · | the diversion of management's attention from ongoing business operations and opportunities; |
| · | dilution caused by Strive's issuance of additional shares of its Class A common stock in connection with the proposed transaction; |
| · | potential adverse reactions of Strive’s or Semler Scientific’s customers or changes to business or employee relationships, including those resulting from the announcement or completion of the proposed transaction; |
| · | changes in Strive’s or Semler Scientific’s share price before closing; |
| · | other factors that may affect future results of Strive, Semler Scientific or the combined company. |
These factors are not necessarily all of the factors that could cause Strive’s, Semler Scientific’s or the combined company's actual results, performance or achievements to differ materially from those expressed in or implied by any of the forward-looking statements. Other factors, including unknown or unpredictable factors, also could harm Strive, Semler Scientific or the combined company's results.
Although each of Strive and Semler Scientific believes that its expectations with respect to forward-looking statements are based upon reasonable assumptions within the bounds of its existing knowledge of its business and operations, there can be no assurance that actual results of Strive or Semler Scientific will not differ materially from any projected future results expressed or implied by such forward-looking statements. Additional factors that could cause results to differ materially from those described above can be found in Strive’s current report on Form 8-K filed with the Securities and Exchange Commission (the SEC) on September 12, 2025 (including the documents incorporated by reference therein), Semler Scientific’s most recent annual report on Form 10-K for the fiscal year ended December 31, 2024 and quarterly reports on Form 10-Q, and other documents subsequently filed by Strive and Semler Scientific with the SEC. The actual results anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on Strive, Semler Scientific or their respective businesses or operations. Investors are cautioned not to rely too heavily on any such forward-looking statements. Forward-looking statements speak only as of the date they are made and Strive and Semler Scientific undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable law.
2
Additional Information and Where to Find It
In connection with the proposed transaction, Strive intends to file with the SEC a Registration Statement on Form S-4 (the "Registration Statement") to register the Class A common stock to be issued by Strive in connection with the proposed transaction and that will include an information statement of Strive, proxy statement of Semler Scientific and a prospectus of Strive (the "Information Statement/Proxy Statement/Prospectus"), and each of Strive and Semler Scientific may file with the SEC other relevant documents concerning the proposed transaction. A definitive Information Statement/Proxy Statement/Prospectus will be sent to the stockholders of Semler Scientific to seek their approval of the proposed transaction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF SEMLER SCIENTIFIC ARE URGED TO READ THE REGISTRATION STATEMENT AND INFORMATION STATEMENT/PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT STRIVE, SEMLER SCIENTIFIC AND THE PROPOSED TRANSACTION AND RELATED MATTERS.
A copy of the Registration Statement, Information Statement/Proxy Statement/Prospectus, as well as other filings containing information about Strive and Semler Scientific, may be obtained, free of charge, at the SEC's website (http://www.sec.gov). You will also be able to obtain these documents, when they are filed, free of charge, from Strive by accessing Strive's website at https://investors.strive.com/. Copies of the Registration Statement, the Information Statement/Proxy Statement/Prospectus and the filings with the SEC that will be incorporated by reference therein can also be obtained, without charge, by directing a request to Strive's Investor Relations department at 200 Crescent Court, Suite 1400, Dallas, Texas 75201 or by calling (855) 427-7360 or by submitting an inquiry at https://investors.strive.com/ir-resources/contact-ir. Copies of the documents filed with the SEC by Semler Scientific will be available free of charge on Semler Scientific’s website at https://ir.semlerscientific.com/. The information on Strive’s or Semler Scientific’s respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.
Participants in the Solicitation
Strive, Semler Scientific and certain of their respective directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Semler Scientific in connection with the proposed transaction. Information about the interests of the directors and executive officers of Strive and Semler Scientific and other persons who may be deemed to be participants in the solicitation of stockholders of Semler Scientific in connection with the proposed transaction and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the Information Statement/Proxy Statement/Prospectus related to the proposed transaction, which will be filed with the SEC. Information about the directors and executive officers of Semler Scientific, their ownership of Semler Scientific common stock, and Semler Scientific’s transactions with related persons is set forth in the section entitled "INFORMATION REGARDING OUR BOARD OF DIRECTORS AND CORPORATE GOVERNANCE," "EXECUTIVE OFFICERS," "SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT," “DIRECTOR COMPENSATION,” and "TRANSACTIONS WITH RELATED PERSONS" included in Semler Scientific’s definitive proxy statement in connection with its 2025 Annual Meeting of Stockholders, as filed with the SEC on July 17, 2025. Additional information regarding ownership of Semler Scientific’s securities by its directors and executive officers is included in such persons’ SEC filings on Forms 3 or 4, which are available at https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001554859. Information about the directors and executive officers of Strive is contained in Strive’s Current Report on Form 8-K filed with the SEC on September 15, 2025, Strive's Current Report on Form 8-K filed with the SEC on September 12, 2025 and under “Meet the Leadership Team” accessed through the “About Us” link on Strive’s website at https://strive.com/team. Additional information regarding ownership of Strive’s securities by its directors and executive officers is included in such persons’ SEC filings on Forms 3 or 4 which are available at https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=1920406. These documents and the other SEC filings described in this paragraph may be obtained free of charge as described above under the heading “Additional Information and Where to Find It.”
No Offer or Solicitation
This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or the solicitation of any vote of approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements.
3
FAQ
What did SMLR disclose in this communication?
Will Semler Scientific (SMLR) stockholders vote on the deal?
Where can investors find the S-4 and related documents?
Is this communication an offer to sell securities?
Who may be participants in the proxy solicitation?
What forward-looking statement cautions are included?
